Phase 2/3 Adaptive Study of VX-147 in Adults With APOL1- Mediated Proteinuric Kidney Disease
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability and
pharmacokinetics (PK) of VX-147 in participants aged 18 years and older with apolipoprotein
L1 (APOL1)-mediated proteinuric kidney disease.